Innate Pharma (IPHA) — Capital Reinvestment Ratio
Latest as of June 2024:
0.09x
Innate Pharma (IPHA) has a Capital Reinvestment Ratio of 0.09x as of June 2024, meaning it reinvests 0% of its operating cash flow ($3.04 Million) in capital expenditures ($283.00K). See Innate Pharma free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.09x
Capex / Operating Cash Flow
Operating Cash Flow
$3.04 Million
USD
Capital Expenditures
$283.00K
USD
Data as of
Jun 2024
Most recent filing
Innate Pharma Capital Reinvestment Ratio (2006–2019)
This chart tracks Innate Pharma's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for Innate Pharma (2006–2019)
Year-by-year Capital Reinvestment Ratio for Innate Pharma from 2006 to 2019. For live market cap and broader valuation context, see market cap of Innate Pharma.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 1.87x | $34.92 Million | $65.40 Million | ▲ +5163.6% |
| 2015 | 0.04x | $207.91 Million | $7.40 Million | ▲ +43.5% |
| 2011 | 0.02x | $12.99 Million | $322.00K | ▼ -98.8% |
| 2006 | 2.09x | $360.00K | $752.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow